金迪克2025年业绩预亏，疫苗研发项目持续推进

Core Viewpoint - The company anticipates a net loss of 160 million to 180 million yuan for 2025, primarily due to increased R&D expenses and asset impairment provisions [2][4] Group 1: Financial Performance - The company has announced a projected net loss of 160 million to 180 million yuan for 2025, representing an increase in losses year-on-year [2] - The loss is attributed to R&D investments, asset impairment provisions, and inventory write-offs totaling approximately 41.99 million yuan [2][4] - Investors are advised to monitor the upcoming annual report for audited financial details [2] Group 2: Product Development Progress - The Phase III clinical trial for the quadrivalent influenza virus split vaccine (for children) has completed participant enrollment and vaccination, with serum currently under inspection by the China Food and Drug Administration [3] - The application for market production of the trivalent influenza virus split vaccine has been accepted, with registration inspections and standard reviews completed, awaiting further evaluation from the National Medical Products Administration [3] - These developments may significantly impact the company's future product line expansion [3]